AKS-452
From Wikipedia, the free encyclopedia
Vaccine candidate against COVID-19
Pharmaceutical compound
TargetSARS-CoV-2
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Protein subunit |
| Clinical data | |
| Routes of administration | Intramuscular |
| Identifiers | |
| CAS Number | |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
|
Medical response |
|
.svg){kind=small} COVID-19 portal |
AKS-452 is a COVID-19 vaccine candidate developed by Akston Biosciences.[2][3]
- ↑ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
- ↑ "Anti-COVID19 AKS-452 – ACT Study (ACT)". ClinicalTrials.gov. 23 December 2020. NCT04681092. Retrieved 21 March 2021.
- ↑ "A study to assess the safety and immunogenicity of Anti-COVID-19 AKS-452 vaccine for SARS-Cov-2 infection in Indian healthy subjects". ctri.nic.in. 11 October 2021. CTRI/2021/10/037269. Retrieved 11 October 2021.
Scholia has a profile for AKS-452 (Q110269780).
| Development | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
| |||||||||||
.png){kind=small} | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |